Active	Status	Sponsor type	Region	Phase	Filter
4 Active 3 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
LONG, Jean-Alexandre
VAPEUR RCT, NCT04838769: REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men	Active, not recruiting	N/A	154	Europe, RoW	REZŪM, alpha blocker and 5-alpha reductase inhibitor, Dual Drug Therapy	Boston Scientific Corporation	Benign Prostatic Hyperplasia (BPH)	02/26	03/27
Descottes, Jean-Luc
No trials found
Arvin-Berod, Alexis
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
LONG, Jean-Alexandre
VAPEUR RCT, NCT04838769: REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men	Active, not recruiting	N/A	154	Europe, RoW	REZŪM, alpha blocker and 5-alpha reductase inhibitor, Dual Drug Therapy	Boston Scientific Corporation	Benign Prostatic Hyperplasia (BPH)	02/26	03/27
Descottes, Jean-Luc
No trials found
Arvin-Berod, Alexis
No trials found